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The aim of this study was to estimate the number of patients discharged from a symptomatic breast clinic who subsequently develop
breast cancer and to determine how many of these cancers had been ‘missed’ at initial assessment. Over a 3-year period, 7004
patients were discharged with a nonmalignant diagnosis. Twenty-nine patients were subsequently diagnosed with breast cancer over
the next 36 months. This equates to a symptomatic ‘interval’ cancer rate of 4.1 per 1000 women in the 36 months after initial
assessment (0.9 per 1000 women within 12 months, 2.6 per 1000 women within 24 months). The lowest sensitivity of initial
assessment was seen in patients of 40–49 years of age, and these patients present the greatest imaging and diagnostic challenge.
Following multidisciplinary review, a consensus was reached on whether a cancer had been missed or not. No delay occurred in
10 patients (35%) and probably no delay in 7 patients (24%). Possible delay occurred in three patients (10%) and definite delay
in diagnosis (i.e., a ‘missed’ cancer) occurred in only nine patients (31%). The overall diagnostic accuracy of ‘triple’ assessment is
99.6% and the ‘missed’ cancer rate is 1.7 per 1000 women discharged.
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The majority of breast cancers in the United Kingdom are detected
in symptomatic women referred by their general practitioners to
breast clinics for further investigation (NHS Information Centre,
2005; UK Statistics Authority, 2005). Breast cancer diagnostic
services have become increasingly streamlined and patients are
frequently seen by multidisciplinary teams (MDTs) in dedicated
breast clinics (Potter et al, 2007). The standard diagnostic process is
referred to as ‘triple assessment’, namely expert clinical breast
examination, breast imaging (a combination of mammography and
ultrasound (US), or both) and, when necessary, needle biopsy
(Britton and Sinnatamby, 2007). The primary aim of ‘symptomatic’
clinics is to separate patients with breast cancer from the majority
(in the region of 93%) who do not (Barber et al, 2004). Inevitably,
however, some patients will be diagnosed with breast cancer having
been recently discharged from a breast clinic with a normal or
benign diagnosis. Although some of these cancers will have
developed de novo, others will have been ‘missed’ at initial
assessment resulting in a delay in diagnosis. Such delay causes
patient anxiety, may affect the clinical outcome and is a major cause
of medical malpractice in the United Kingdom (Barber et al, 2004).
When the National Health Services Breast Screening Programme
(NHSBSP) was set up in 1988, its performance was managed by a
strong quality assurance programme using nationally set targets
and regional quality assurance team inspections (NHS Breast
Screening Programme, 2000, 2005a,b). Screened women with a
normal result who subsequently develop breast cancer before their
next screening invitation are referred to as having developed an
interval cancer. A screening programme interval cancer rate can
be used as a performance indicator, and NHSBSP standards for
interval cancer rates are published (NHS Breast Screening
Programme, 2005b).
The ‘symptomatic’ service has far less rigorous monitoring.
Following the publication of the updated National Institute for
Clinical Excellence (NICE) guidance in 2002, all designated breast
cancer MDTs were reviewed by a team of clinical peers, and a total
of 174 breast cancer MDTs were inspected as part of this 2004–
2007 peer review round (National Institute for Clinical Excellence,
2002, 2008). There are currently no guidelines for acceptable
sensitivity and specificity for diagnostic accuracy in such clinics.
The aim of this study was to calculate the number of patients
discharged from a symptomatic breast clinic who develop breast
cancer within the subsequent 3 years (effectively an interval cancer
rate for the symptomatic service) and to determine how many of
these cancers had been ‘missed’ at initial assessment.
MATERIALS AND METHODS
All new patients referred to a specialist breast unit by their general
practitioners from 1 January 2001 to 31 December 2003 were
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sidentified using a dedicated database. The investigation and
management of patients were carried out according to local
department protocols that have been adapted from national
guidelines (Royal College of Radiologists, 2003; The Association
of Breast Surgery, 2005). All patients underwent a careful clinical
breast examination, and the degree of clinical suspicion was
recorded using a 5-point scale (E1 normal–E5 clinically malig-
nant). All patients over the age of 35 years underwent bilateral
mammography, and any patient with a focal clinical or radiological
abnormality has a targeted US. The imaging results were also
recorded on a 5-point scale as for clinical examination. Any patient
with clinically suspicious or focal solid abnormality underwent
a core biopsy. All patients who underwent breast needle biopsy
are subsequently discussed at a multidisciplinary meeting to
decide on future management. All data are entered onto a
dedicated breast database, the Joint Clinical Information System
(JCIS), which is an n-tier web-based clinical information system
supported by a SQL Server database. The system was built in-
house in partnership with the breast clinical team using i5 Web
application and Microsoft technologies including Visual Basic
(Dataline Software Ltd, Brighton, UK). The system is designed to
assist in the management and care of cancer patients by providing
tools for clinicians to enter coded data at the point of care and to
re-use that information for clinical notes, letters, waiting times
performance management, clinical audit and research.
Each patient discharged during this period with a noncancer
diagnosis was traced through the database for a further 3 years.
Those patients who were subsequently diagnosed with breast
cancer whether in the symptomatic clinic or breast screening
programme were then identified. The age of the patient and length
of time between initial presentation and subsequent cancer
diagnosis were also recorded. The sensitivity of initial assessment
examination was calculated as the proportion of cancers that were
detected at the first assessment compared with the total number of
cancers developing in each age group over the 3-year period.
Correlation was also determined using histological findings of
subsequent malignancy. The clinical details and imaging of the
initial clinic visit were reviewed blinded to the clinical and imaging
features of the subsequently diagnosed breast cancer. The clinician
performed the breast examination, and the degree of clinical
suspicion was noted. Mammographic breast density (according to
the Breast Imaging Reporting and Data System (BI-RADS)) (D’Orsi
et al, 2003), initial mammography and US report and any
interventional procedures were noted. Imaging review was
classified into one of the four categories according to the NHSBSP
guidelines as follows: if imaging was unavailable, then imaging
assessment was designated unclassifiable; normal/benign or true
interval cancer if there were no suspicious features seen on prior
imaging; uncertain or minimal signs interval cancer if mammo-
graphic changes were neither clearly benign or malignant; and
suspicious or missed if the mammographic features were
suspicious of malignancy (NHS Breast Screening Programme,
2005b). Thereafter, review was unblinded to assess whether
uncertain or suspicious features were in the same breast and
location as the subsequent diagnosis of cancer.
Following multidisciplinary review of both clinical and imaging
investigations, a final symptomatic interval cancer classification
was ascribed. These were as follows: no delay for patients
presenting with a different problem and where review of previous
clinical and imaging showed no suspicious findings; probably no
delay for patients presenting with a different problem, but no
images were available for review; possible delay for patients
presenting with a different problem, but review of case showed
subtle evidence of malignancy; delay in diagnosis (or ‘missed’) for
patients presenting with the same problem that was subsequently
diagnosed as breast cancer (whether imaging was available for
review or not). For those patients whose imaging was unavailable
for review, a designation of probably no delay or delay was given
based on the available clinical information and imaging reports.
The authors tended to err on the side of ‘worse’ classification (i.e.,
delay rather than probably no delay) so that the ‘miss’ rate was not
underestimated.
Poisson regression was used to analyse categorical data, yielding
likelihood-ratio w
2 tests, including tests for trend where data were
ordered. Linear regression was used to analyse continuous end
points, such as tumour size.
RESULTS
A total of 7613 new symptomatic patients were referred to the
breast unit between 1 January 2001 and 31 December 2003, and of
these, 609 patients (8.0%) were diagnosed with breast cancer. In
total, 7004 patients were discharged from the clinic with a
noncancer diagnosis, of whom, only 126 (1.8%) had further clinic
appointments for a formal follow-up of their initial complaint. The
remainder were discharged without follow-up; however, 2195
(31%) were re-referred by their general practitioner for further
appointment(s) (ranging between 1 and 5 appointments). Of these
patients, 29 were diagnosed with breast cancer in the 3 years after
discharge and constituted the study cohort in this paper. All of
these patients were diagnosed in the symptomatic clinic and none
by screening mammography.
The age distribution of each of these three groups is shown in
Figure 1. Patients with breast cancer diagnosed at initial clinic visit
and in the subsequent 3 years were significantly older than those
discharged and remaining free of disease (Po0.001 and P¼0.02,
respectively). Patients with subsequently diagnosed cancer were
younger (mean age 55 years) than those diagnosed at initial visit
(mean age 62 years), although this did not reach statistical
significance (P¼0.07). Apart from the youngest ages, where
numbers are extremely small, the sensitivity of the initial
assessment for the diagnosis of cancer rises with age (see Figure 1).
The lowest sensitivity of initial assessment was seen in women
aged 40–49 years. Of the 29 patients who were subsequently
diagnosed with breast cancer within 36 months, 6 were diagnosed
within 12 months and 18 within 24 months. This equates to a
symptomatic ‘interval’ cancer rate of 0.9 per 1000 women within 12
months, 2.6 per 1000 women within 24 months and 4.1 per 1000
women in the 36 months after the initial assessment (see Table 1).
Time from initial assessment was not significantly related to
patient tumour size, node status, grade, Nottingham Prognostic
Index, breast density or oestrogen receptor status. There was a
suggestive but nonsignificant finding that a longer interval was
associated with greater age (P¼0.09).
All available imaging performed at the time of initial assessment
was reviewed by a panel of experienced breast radiologists, who
were aware that the patient had developed breast cancer but not of
its side or site. Imaging was unavailable for review in 14 (48%)
patients. There were no suspicious features seen on prior imaging
at the site of subsequent cancer development in 10 (35%) patients.
There were minimal signs of malignancy in 4 (14%) patients (2
subtle parenchymal deformity, 1 small cluster of microcalcification
and 1 mammographic asymmetry). The mammogram of one
patient showed a small mass lesion away from the presenting
clinical complaint that was overlooked at the initial assessment
and was designated a suspicious or a ‘missed’ interval cancer.
The multidisciplinary final case classification was as follows: no
delay in diagnosis in 10 (35%) patients; probably no delay in 7
(24%) patients; possible delay in 3 (10%) patients; and delay in
diagnosis in 9 (31%) patients (Table 2 and Figure 2). The
likelihood of delay in diagnosis was not significantly associated
with patient’s age or breast density. Tumours where a delay in
diagnosis was suspected were significantly larger (mean 33 vs
23mm diameter; P¼0.03) and had significantly more involved
nodes (median of 1 vs 6 nodes; P¼0.03), compared with those
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swhere no delay was suspected. Grade and oestrogen receptor status
were not significantly different.
The initial presentations of the 12 patients with delay or possible
delay in diagnosis were varied (lump 9, nipple discharge 1, breast
pain 1 and nipple eczema 1). Clinical examination was performed
by a consultant nurse practitioner or consultant breast surgeon in
8 (67%), surgical trainee in 3 (25%) and an experienced associate
specialist in breast disease in 1 (8%) patient. Clinical examination
findings in the breast subsequently diagnosed with cancer were
designated normal (E1) in 2, benign (E2) in 8 and suspicious
probably benign (E3) in 2 patients. None had more suspicious
findings. All patients underwent bilateral mammography as part of
their initial imaging assessment. The breast density was BI-RADS
category 1 (o25% fibroglandular tissue) in 1, category 2 (26–50%
fibroglandular tissue) in 1, category 3 (51–75% fibroglandular
tissue) in 6 (55%) and category 4 (475% fibroglandular tissue) in
4 patients. Mammographic interpretation of the breast that
subsequently was diagnosed with breast cancer was reported as
normal in 8 (67%) and benign in 4 (33%) patients. Ultrasound was
performed in eight patients, of which four were reported normal and
four were benign. The radiological examination was undertaken and
reported by a consultant breast radiologist in 10 (83%) and by a
supervised radiologist in training in 2 (17%) patients. One patient
underwent a punch biopsy of the nipple and one a cytological smear
of nipple discharge all of which produced benign results.
DISCUSSION
We have calculated the interval cancer rate for patients discharged
from a symptomatic breast clinic with a nonmalignant diagnosis.
The ability to carry out this audit, and the high quality of the data,
has only been possible as a result of prospective data collection
using the JCIS, an electronic record for cancer patients. Although
the population is different from that seen in a screening
programme (largely women between 50 and 70 years in the
NHSBSP), it is of interest to compare the relative interval cancer
rates. The expected standard target in the NHSBSP for interval
cancer rate is o1.2 per 1000 women screened in the first 2 years
and 1.4 per 1000 women screened in the third year (NHS Breast
Screening Programme, 2005b). Reported interval cancer data from
Breast Test Wales is 0.7 per 1000 women screened in the first year,
Interval cancers
diagnosed in 3 years
after discharge
Cancer diagnosed
at initial assessment
Patients discharged
after initial
assessment
20%
40%
60%
80%
100%
98 99 95 93 92 96 Sensitivity (%)
1 1 1 5 8 11 2 0 0 Interval cancers diagnosed in 3 
years after discharge
20 96 117 91 109 127 45 4 0 Cancer diagnosed at initial 
assessment
32 211 481 638 1422 2122 1630 784 229 Patients discharged after initial 
assessment
90+ 80–89 70–79 60–69 50–59 40–49 30–39 20–29 0–20 Age (years)
Figure 1 Graph showing the age distribution of 7004 patients discharged from a symptomatic breast clinic after an initial assessment, 609 patients
diagnosed with breast cancer at the initial assessment and 29 patients diagnosed with an ‘interval’ cancer in the 3 years after discharge after an initial
assessment. The sensitivity of initial assessment examination is derived from the proportion of cancers that were detected at the first assessment compared
with the total number of cancers developing in each age group over the 3-year period.
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s1.3 in the second and 1.6 in the third year (Breast Test Wales,
2005). The equivalent rates from our symptomatic population are
very similar to these data at 0.9 per 1000 women in the first year,
1.7 within the second year and 1.6 in the third year after an initial
assessment (see Table 1). As these data are from a single unit, any
patient developing breast cancer after discharge and presenting to
another centre would not be included resulting in an under-
estimate of the interval cancer rate. As the local population
demographic is one of net influx, this should mitigate against this
being a significant under ascertainment. These figures equate to a
diagnostic accuracy of 99.6%. It is important to note that all
patients undergoing needle biopsy were discussed at a multi-
disciplinary meeting in contrast to many breast units where only
breast cancers are discussed. This allows time for discussion of
difficult diagnostic cases and almost certainly contributes to this
very high level of diagnostic accuracy. The choice of biopsy
technique may well also be important. During this study period,
wide bore needle core biopsy with histopathological diagnosis was
Table 1 The histopathological findings and length of time from initial assessment of 29 patients who were diagnosed with breast cancer having been
previously discharged from the breast clinic.
Histopathology of interval cancer
Interval between
initial assessment
and interval
cancer (months)
No. of
patients
Mean age
years
(range)
Mammographic
density
(BI-RADS 1–4)
Mean
size mm
(range) Grade
Nodal
status
a
ER
status
% of patients with
NPI 43.4 (moderate/
poor/very poor
prognostic groups)
b
Interval cancer rate
per 1000 patients
discharged from a
symptomatic clinic
0–12
c 6 49 (39–56) 1: 0
2: 0
3: 3
4: 3
29 (8–52) Gd 1: 0
Gd 2: 2
Gd 3: 3
1: 2
2: 1
3: 2
+ve 4
 ve 1
60 0.9
13–24 12 57 (41–96) 1: 2
2: 1
3: 3
4: 6
29 (9–60) Gd 1: 1
Gd 2: 4
Gd 3: 7
1: 4
2: 4
3: 4
+ve 6
 ve 6
91 1.7
25–36 11 56 (38–87) 1: 0
2: 0
3: 10
4: 1
25 (18–40) Gd 1: 1
Gd 2: 2
Gd 3: 8
1: 5
2: 4
3: 2
+ve 8
 ve 3
91 1.6
Total
c 29 55 (38–96) 1: 2
2: 1
3: 16
4: 10
27 (8–60) Gd 1: 2
Gd 2: 8
Gd 3: 18
1: 11
2: 9
3: 8
+ve 18
 ve 10
86 4.1
aAccording to the Nottingham Prognostic Index (Blamey et al, 2007a,b).
bNPI indicates Nottingham Prognostic Index (Blamey et al, 2007a,b).
cFinal histology unknown in one
patient who emigrated and underwent treatment abroad.
Table 2 The histopathological findings and classification of whether a delay in diagnosis had occurred of 29 patients who were diagnosed with breast
cancer having been previously discharged from the breast clinic.
Histopathology of ‘interval’ cancer
Classification
of interval
cancer
No. of
patients
Mean age
years
(range)
Mean time from
initial discharge
to diagnosis of
breast cancer
(months)
Mammographic
density
(BI-RADS 1–4)
Imaging
review
classification
a
Mean
size mm
(range) Grade
Nodal
status
b
ER
status
% of patients with
NPI 43.4
(moderate/
poor/very poor
prognostic groups)
c
Interval cancer
rate per 1000
patients seen
in a symptomatic
clinic
No delay 10 50 (41–56) 19.4 1: 0
2: 0
3: 6
4: 4
10 Normal/benign 20 (8–33) Gd 1: 1
Gd 2: 3
Gd 3: 6
1: 5
2: 3
3: 2
+ve 5
 ve 5
70 1.4
Probably no
delay
7 58 (39–87) 23.6 1: 1
2: 0
3: 4
4: 2
7 Unclassifiable 29 (17–50) Gd 1: 0
Gd 2: 0
Gd 3: 7
1: 4
2: 3
3: 0
+ve 5
 ve 2
100 1.0
Possible delay 3 59 (53–69) 17.3 1: 0
2: 1
3: 1
4: 1
3 Uncertain 33 (16–52) Gd 1: 1
Gd 2: 1
Gd 3: 1
1: 1
2: 1
3: 1
+ve 3
 ve 0
66 0.4
Delay
d 9 57 (36–96) 21.8 1: 1
2: 0
3: 5
4: 3
7 Unclassifiable
1 Uncertain
1 Suspicious
33 (20–60) Gd 1: 0
Gd 2: 4
Gd 3: 4
1: 1
2: 3
3: 4
+ve 5
 ve 3
100 1.3
Total
d 29 55 (38–96) 20.9 1: 2
2: 1
3: 16
4: 10
27 (8–60) Gd 1: 2
Gd 2: 8
Gd 3: 18
1: 11
2: 9
3: 8
+ve 18
 ve 10
86 4.1
aImaging Review Classification: Unclassifiable (imaging unavailable for review), normal/benign (no suspicious features), uncertain (neither clearly benign or malignant imaging
changes), suspicious (‘missed’ cancer).
bAccording to the Nottingham Prognostic Index (Blamey et al, 2007a,b).
cNPI indicates Nottingham Prognostic Index (Blamey et al,
2007a,b).
dFinal histology unknown in one patient who emigrated and underwent treatment abroad.
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sthe only method used having been shown earlier to be superior to
fine needle aspiration cytology (Britton, 1999).
Were mistakes made at initial assessment that might have
contributed to a delay in diagnosis? Over 80% of the patients who
developed an interval cancer were examined by experienced
consultants or specialist practitioners. Although this reflects our
practice of the clinical examination not being performed by
trainees without very close supervision, our policy has become
more rigorous since that described in the initial study period
of 2001–2003. Any individual now undertaking clinical breast
examination has to carry out an audit of breast and axillary
examination of at least 500 patients and requires a 90%
concordance with a consultant examination (Chapman et al,
2002). This section of the advanced practitioner course often forms
part of an MSc degree. Similarly, a consultant breast radiologist
supervised the imaging in all 29 patients and directly performed
the examination in over 80% of the patients. Only 1 (3%) patient
had a definite abnormality that was overlooked on initial
mammographic examination and the images of 4 (14%) patients
showed subtle abnormalities. It is unfortunate, however, that
imaging for 14 (48%) of the patients was unavailable for review
and reflects a policy of aggressive film culling within the NHS
because of lack of the film storage space. As stated earlier, the
authors tended to err on the side of ‘worse’ classification (i.e.,
delay rather than probably no delay) so that the ‘miss’ rate was not
falsely underestimated. However, the missing images do weaken
the robustness of the final case classification. The authors felt that
the lack of images should not exclude a patient from being
included in the series, as this would result in a misleadingly
underestimate of the missed cancer rate.
We have calculated the sensitivity of the initial assessment as the
proportion of cancers that were detected at the first assessment
compared with the total number of cancers developing in each age
group over the 3-year period. These data will include cancers
that were either not present or undetectable at the time of initial
assessment. The lowest sensitivity of initial assessment was seen in
women aged 40–49 years. This is not surprising as patients in this
age group, with denser breasts and higher levels of benign
pathology, present the greatest imaging and diagnostic challenges.
This is well illustrated by the fact that 90% of the interval cancer
patients had dense or very dense mammograms.
A multidisciplinary meeting reached a consensus decision that just
over 30% of patients developing an interval cancer after a sympto-
matic assessment did present with the same problem as was subse-
quently diagnosed as breast cancer resulting in a delay in diagnosis.
An additional 10% of patients had a possible delay in diagnosis.
Unlike many breast units, all patients in this series were seen in
a one-stop multidisciplinary clinic with access to same day
imaging and biopsy. A key part of the Cancer Reform Strategy
(UK Department of Health, 2007) is a maximum 2-week wait for all
breast referrals by December 2009, and there is no doubt that the
provision of one-stop assessment for all patients can facilitate this.
The data from this audit can reassure both clinicians and patients
that one-stop breast clinics provide high-quality diagnostic
accuracy, with very few missed cancers, and contribute to early
breast cancer diagnosis and treatment.
SUMMARY
We have shown that triple assessment carried out in an MDT
setting is extremely safe with an overall diagnostic accuracy of
99.6%. The lowest sensitivity for initial assessment occurs in
younger women aged 40–49 years. For every 1000 patients seen
and discharged, just over 4 will return and be diagnosed with
breast cancer in the following 3 years. Of these, 1.3 will have been
unequivocally missed at the initial presentation and a further 0.4
will have had a subtle imaging abnormality that was overlooked at
the initial assessment. The ‘missed’ cancer rate overall is therefore
1.7 per 1000 women discharged over a 3-year period.
ACKNOWLEDGEMENTS
PB, GCW, RS, MW, SB, MG and PF were supported with research
funding from the National Institute for Health Research Cambridge
Biomedical Research Centre (NIRH Cambridge BMRC). SWD was
funded by Cancer Research UK. A O’Neill is funded by Cancer
Research UK and the NIRH Cambridge BMRC. The JCIS team is
funded by Cancer Research UK and by the NIRH Cambridge BMRC.
All the research data and conclusions presented by the authors are
independent of influence from the above funding bodies. The
funding source had no involvement in the undertaking or writing of
this paper. The authors thank all members of the Cambridge Breast
Unit for their commitment to high-quality patient care as evidenced
by their adherence to the unit protocol and accurate data collection.
REFERENCES
Barber MD, Jack W, Dixon JM (2004) Diagnostic delay in breast cancer.
Br J Surg 91: 49–53
Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ,
Haybittle JL (2007a) Reading the prognosis of the individual with breast
cancer. Eur J Cancer 43: 1545–1547
Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA,
Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW (2007b)
Survival of invasive breast cancer according to the Nottingham
Prognostic Index in cases diagnosed in 1990–1999. Eur J Cancer 43:
1548–1555
AB
Figure 2 (A) The mammogram of a 58-year old patient referred with an
8-week history of a clinically benign (E2) lump inferior to the right nipple,
reported as normal at initial assessment and subsequent review. A breast
ultrasound (US) of the palpable lump by a consultant radiologist found no
suspicious abnormality and the patient was discharged. (B) Mammogram
taken 2 years later when the patient re-presented stating that the lump had
enlarged and clinical examination showed a clinically malignant (E5)
abnormality, shows an obvious large bilobed mass (arrows) suspicious for
malignancy, which was confirmed on US. A core biopsy showed a
metaplastic carcinoma.
How often are breast cancers missed?
P Britton et al
1877
British Journal of Cancer (2009) 100(12), 1873–1878 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sBreast Test Wales (2005) Report of the Director 2005. NHS Wales. Available
at http://www.screeningservices.org.uk/btw
Britton PD (1999) Fine needle aspiration or core biopsy. The Breast
8: 1–4
Britton P, Sinnatamby R (2007) The investigation of suspected breast
cancer. BMJ 335: 347–348
Chapman D, Purushotham A, Wishart G (2002) Nurse practitioner training
in breast examination. Nurs Stand 17: 33–36
D’Orsi CJ, Bassett LW, Berg WA (2003) Breast Imaging Reporting
and Data System: ACR BI-RADS-Mammography, 4th edn,
American College of Radiology: Reston, VA. Available at http://
www.acr.org
NHS Breast Screening Programme (2000) Guidelines on Quality Assurance
Visits NHSBSP Publication No. 40 Second edition. Available at http://
www.cancerscreening.nhs.uk
NHS Breast Screening Programme (2005a) Quality Assurance Guidelines
for Breast Cancer Screening Radiology NHSBSP Publication No. 59.
Available at http://www.cancerscreening.nhs.uk
NHS Breast Screening Programme (2005b) Consolidated Guidance on
Standards for the NHSBSP Publication No. 60 (Version 2). Available
at http://www.cancerscreening.nhs.uk
NHS Information Centre (2005) http://www.ic.nhs.uk/statistics-and-data-
collections/screening/breast-cancer/breast-screening-programme-england-
2004-05. Accessed on 5 September 2008
National Institute for Clinical Excellence (2002) Guidance on Cancer
Services. Improving Outcomes in Breast Cancer – Manual Update. COG
Guidelines; available at http://www.nice.org.uk
National Institute for Clinical Excellence (2008) Early and locally advanced breast
cancer: full guideline draft for consultation. Available at http://www.nice.org.uk
Potter S, Govindarajulu S, Shere M, Braddon F, Curran G, Greenwood R,
Sahu AK, Cawthorn SJ (2007) Referral patterns, cancer diagnoses, and
waiting times after introduction of two week wait rule for breast cancer: a
prospective cohort study. BMJ 335: 288
Royal College of Radiologists (2003) Guidance on Screening and
Symptomatic Breast Imaging (Second Edition). The Royal College of
Radiologists 2003 ISBN 1 872599 850
The Association of Breast Surgery (BASO) (2005) Guidelines for the
management of symptomatic breast disease. EJSO 31: S1–S21
UK Department of Health (2007) Cancer Reform Strategy. Department of
Health: London. Available at http://www.dh.gov.uk
UK Statistics Authority (2005). Available at http://www.statistics.gov.uk.
Accessed on 5 September 2008
How often are breast cancers missed?
P Britton et al
1878
British Journal of Cancer (2009) 100(12), 1873–1878 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s